Capricor Therapeutics (NASDAQ:CAPR) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?

Capricor Therapeutics Inc (NASDAQ:CAPR)’s stock price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $12.95 and traded as high as $19.30. Capricor Therapeutics shares last traded at $18.45, with a volume of 652,168 shares.

Analysts Set New Price Targets

Several equities research analysts have commented on CAPR shares. Oppenheimer restated an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 price objective on shares of Capricor Therapeutics in a research note on Friday, September 20th. Maxim Group boosted their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Piper Sandler started coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, October 9th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $24.67.

Capricor Therapeutics Trading Down 0.8 %

The stock’s 50-day simple moving average is $12.95 and its 200-day simple moving average is $7.75. The stock has a market cap of $837.74 million, a price-to-earnings ratio of -19.84 and a beta of 4.00.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The firm had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. On average, equities research analysts forecast that Capricor Therapeutics Inc will post -1.17 earnings per share for the current year.

Insider Transactions at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the business’s stock in a transaction on Friday, September 20th. The shares were purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 12.00% of the stock is currently owned by insiders.

Institutional Trading of Capricor Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CAPR. BNP Paribas Financial Markets acquired a new position in shares of Capricor Therapeutics during the first quarter worth $40,000. Main Street Financial Solutions LLC lifted its holdings in shares of Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares during the period. SG Americas Securities LLC acquired a new position in shares of Capricor Therapeutics during the third quarter worth $133,000. Bank of New York Mellon Corp lifted its holdings in shares of Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares during the period. Finally, Oppenheimer & Co. Inc. lifted its holdings in shares of Capricor Therapeutics by 25.2% during the third quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company’s stock worth $1,040,000 after purchasing an additional 13,762 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.